Dosimetry-Based Consideration on Remission and Relapse after Therapy with 223Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report
Anna Maria Mangano,
Massimiliano Pacilio,
Pasquale Ialongo,
Alessandro Semprebene,
Guido Ventroni,
Lucio Mango
Affiliations
Anna Maria Mangano
Nuclear Medicine Department, “S. Camillo-Forlanini” General Hospital, 00152 Rome, Italy
Massimiliano Pacilio
Medical Physics Unit, “Policlinico Umberto I” University Hospital, 00161 Rome, Italy
Pasquale Ialongo
Radiology, “S. Camillo-Forlanini” General Hospital, 00152 Rome, Italy
Alessandro Semprebene
Nuclear Medicine Department, “S. Camillo-Forlanini” General Hospital, 00152 Rome, Italy
Guido Ventroni
Nuclear Medicine Department, “S. Camillo-Forlanini” General Hospital, 00152 Rome, Italy
Lucio Mango
Nuclear Medicine Department, “S. Camillo-Forlanini” General Hospital, 00152 Rome, Italy
Here, we present the case of a 64-year-old male patient diagnosed with castration-resistant prostate cancer (CRPC) with bone metastasis, treated with abiraterone prednisone/prednisolone in combination with 223Ra-dichloride therapy, who had remission and a subsequent relapse of bone metastasis on repeated bone scans after therapy. We also discuss the possibility of continuing the 223Ra-dichloride therapy over the six planned administrations by administering other cycles at the same dose or at higher doses, if shown to be devoid of a significant increase in side effects, based on dosimetry considerations.
